Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against NVE Corporation. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is NVE Corporation (NVEC) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of NVE Corporation (NASDAQ: NVEC).
On October 21, 2026, NVE reported its financial results for the second quarter of fiscal 2027, revealing, among other things, that, quarter over quarter, revenue decreased 47%, product sales decreased 48%, gross profit decreased 49%, and diluted EPS decreased 51%. During the Company’s earnings call, Principal Financial Officer Daniel Nelson stated that “[t]he decrease in product sales was due to a short-term inventory adjustment at one of our large medical device customers and a 95% decrease in defense product sales.” Nelson further stated that “we expect revenues in the second half of the fiscal year to be consistent with the first half.” The Company’s CEO, Peter Eames, explained that the “variability was primarily from orders being pulled into quarter 1 from quarter 2.” Following this news, NVE’s stock price dropped as much as $31.56, or 30.62%.
What Potential Securities Violations Is BG&G Investigating?
- Whether NVE Corporation and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether NVE Corporation failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Should NVE Corporation (NVEC) Investors Do?
How Did NVE Corporation (NVEC) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”